Shire Pharmaceuticals Acquires Lotus Tissue Repair for Undisclosed Sum

  • Feed Type
  • Date
    1/9/2013
  • Company Name
    Lotus Tissue Repair
  • Mailing Address
    One Mifflin Place Cambridge, MA 02138
  • Company Description
    Lotus Tissue Repair is developing its proprietary recombinant human collagen Type VII (rC7) technology as a treatment for dermatologic conditions in which rC7 may play an important role in accelerating chronic wound healing, such as diabetic foot ulcers, venous stasis ulcers and similar conditions.
  • Website
    http://www.lotustissuerepair.com
  • Transaction Type
    M&A
  • Transaction Amount
    Undisclosed
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    Shire will purchase the company for an upfront payment and certain contingent payments based on the achievement of certain safety and development milestones.

By posting a comment, you agree to our terms and conditions.